LLY

824.65

+1.39%↑

UNH

499.07

+2.21%↑

JNJ

163.02

+0.06%↑

NVO

80.29

+3.98%↑

ABBV

214.79

+1.37%↑

LLY

824.65

+1.39%↑

UNH

499.07

+2.21%↑

JNJ

163.02

+0.06%↑

NVO

80.29

+3.98%↑

ABBV

214.79

+1.37%↑

LLY

824.65

+1.39%↑

UNH

499.07

+2.21%↑

JNJ

163.02

+0.06%↑

NVO

80.29

+3.98%↑

ABBV

214.79

+1.37%↑

LLY

824.65

+1.39%↑

UNH

499.07

+2.21%↑

JNJ

163.02

+0.06%↑

NVO

80.29

+3.98%↑

ABBV

214.79

+1.37%↑

LLY

824.65

+1.39%↑

UNH

499.07

+2.21%↑

JNJ

163.02

+0.06%↑

NVO

80.29

+3.98%↑

ABBV

214.79

+1.37%↑

Search

BioNTech SE ADR

Cerrado

Sector Salud

100.82 1.35

Resumen

Variación precio

24h

Actual

Mínimo

98.98

Máximo

102.4

Métricas clave

By Trading Economics

Ingresos

965M

159M

Ventas

1.1B

1.2B

BPA

1.08

Margen de beneficio

12.749

Empleados

6,133

EBITDA

960M

211M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+41.21 upside

Dividendos

By Dow Jones

Próximas Ganancias

5 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

26B

Apertura anterior

99.47

Cierre anterior

100.82

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

BioNTech SE ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

4 feb 2025, 18:52 UTC

Principales Movimientos del Mercado

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

15 nov 2024, 10:28 UTC

Principales Movimientos del Mercado

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

6 may 2024, 11:27 UTC

Ganancias

BioNTech Swings to Net Loss on Lower Covid Vaccine Sales

20 mar 2024, 10:44 UTC

Ganancias

BioNTech Profit Slumps on Lower Covid Vaccine Sales

15 nov 2024, 11:14 UTC

Charlas de Mercado

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

15 nov 2024, 10:34 UTC

Charlas de Mercado

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

5 ago 2024, 10:02 UTC

Ganancias

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

5 ago 2024, 10:01 UTC

Ganancias

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

5 ago 2024, 10:01 UTC

Ganancias

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

5 ago 2024, 10:00 UTC

Ganancias

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

5 ago 2024, 09:59 UTC

Ganancias

BioNTech 2Q Loss EUR807.8M >BNTX

5 ago 2024, 09:59 UTC

Ganancias

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

5 ago 2024, 09:59 UTC

Ganancias

BioNTech 2Q Rev EUR128.7M >BNTX

6 may 2024, 20:15 UTC

Ganancias

BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come -- IBD

6 may 2024, 10:47 UTC

Ganancias

BioNTech Sees FY24 Rev EUR2.5B-EUR3.1B >BNTX

6 may 2024, 10:46 UTC

Ganancias

Correct: BioNTech 1Q Loss/Shr EUR1.31 >BNTX

6 may 2024, 10:46 UTC

Ganancias

Correct: BioNTech 1Q Loss EUR315.1M >BNTX

6 may 2024, 10:46 UTC

Ganancias

Correct: BioNTech 1Q Rev EUR187.6M >BNTX

6 may 2024, 10:45 UTC

Ganancias

BioNTech 1Q Rev $187.6M >BNTX

6 may 2024, 10:45 UTC

Ganancias

BioNTech 1Q Loss $315.1M >BNTX

6 may 2024, 10:45 UTC

Ganancias

BioNTech 1Q Loss/Shr $1.31 >BNTX

26 mar 2024, 05:00 UTC

Ganancias

This Vaccine Maker Sits on Cash Almost Equal to Its Market Value -- Barrons.com

20 mar 2024, 11:44 UTC

Ganancias

BioNTech Earnings Fall Short of Estimates. The Stock Is Down. -- Barrons.com

20 mar 2024, 10:27 UTC

Ganancias

BioNTech's Stock Sinks After Earnings Fall Below Expectations, Hurt By Writedowns Of Vaccine Inventory -- MarketWatch

20 mar 2024, 10:17 UTC

Ganancias

BioNTech 4Q Rev EUR1.48B >BNTX

20 mar 2024, 10:15 UTC

Ganancias

Biontech 4Q Net Pft EUR457.9M

20 mar 2024, 10:15 UTC

Ganancias

Biontech Plans For Ten or More Registrational Oncology Trials By End of 2024

20 mar 2024, 10:15 UTC

Ganancias

Biontech: Annemarie Hanekamp appointed to Management Board as Chief Commercial Officer, effective Jul. 1

20 mar 2024, 10:15 UTC

Ganancias

Biontech Aims For First Oncology Launch in 2026 and Ten Indication Approvals by 2030

20 mar 2024, 10:15 UTC

Ganancias

Biontech 2023 Gross Profit For COVID-19 Vaccine Business EUR3.2B

Comparación entre iguales

Cambio de precio

BioNTech SE ADR Esperado

Precio Objetivo

By TipRanks

41.21% repunte

Estimación a 12 meses

Media 140.46 USD  41.21%

Máximo 171.44 USD

Mínimo 110 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioNTech SE ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

12

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

99.47 / 111Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac